YIPSCELL Trademark

Trademark Overview


On Friday, October 9, 2020, a trademark application was filed for YIPSCELL with the United States Patent and Trademark Office. The USPTO has given the YIPSCELL trademark a serial number of 90244106. The federal status of this trademark filing is REGISTERED as of Tuesday, May 31, 2022. This trademark is owned by CiSTEM Inc.. The YIPSCELL trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

pharmaceutical preparations for the treatment of musculo-skeletal disorders, damaged skin and tissue, and for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for treating and preventing knee cartilage and meniscus injuries and disorders, and for knee cartilage and meniscus regeneration; medicinal preparations for musculo-skeletal disorders, damaged skin and tissue, and for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for treating and preventing knee cartilage and meniscus injuries and disorders, and for knee cartilage and meniscus regeneration; biochemical preparations for medical purposes, namely, for the diagnosis and treatment of musculo-skeletal disorders, damaged skin and tissue, and for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for treating and preventing knee cartilage and meniscus injuries and disorders, and for knee cartilage and...

stem cell research services; research and development services in the field of cytology; custom cell culturing services for scientific and research purposes; testing, inspection, research and development of cell and tissue culturing; research and development of medicines; scientific investigations for medical purposes; custom design and development of chemical reagents scientific services relating to the isolation and cultivation of human tissues and cells for research purposes; research and development and consultation related thereto in the field of antibodies, antibody technology, chemistry, agrochemical pharmaceuticals, bioinformatics, biomedical devices, biologics, biotechnology, biotherapeutics, biology, biochemical preparations, cell lines, chemoinformatic, genetics and genetic engineering, gene expression systems, in vitro research, inhalation pharmaceuticals, molecular sciences, micro-organisms, nutrition, ophthalmic preparations, pharmacogenetics, pharmacokinetics, pharmacolo...
yipscell

General Information


Serial Number90244106
Word MarkYIPSCELL
Filing DateFriday, October 9, 2020
Status700 - REGISTERED
Status DateTuesday, May 31, 2022
Registration Number6747871
Registration DateTuesday, May 31, 2022
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 14, 2021

Trademark Statements


Goods and Servicespharmaceutical preparations for the treatment of musculo-skeletal disorders, damaged skin and tissue, and for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for treating and preventing knee cartilage and meniscus injuries and disorders, and for knee cartilage and meniscus regeneration; medicinal preparations for musculo-skeletal disorders, damaged skin and tissue, and for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for treating and preventing knee cartilage and meniscus injuries and disorders, and for knee cartilage and meniscus regeneration; biochemical preparations for medical purposes, namely, for the diagnosis and treatment of musculo-skeletal disorders, damaged skin and tissue, and for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for treating and preventing knee cartilage and meniscus injuries and disorders, and for knee cartilage and meniscus regeneration; pharmaceutical preparations for the treatment of viral and infectious diseases, autoimmune diseases, kidney diseases, hepatic diseases, neurological diseases and bone diseases; stem cells for medical and veterinary purposes; cultured cells comprised of stem cells for medical use, namely, injection and impanation for treatment of cartilage and meniscus injuries; cells for medical use; cellular function activating agents for medical purposes; cell growth media for growing cells for medical use; reagent kits for medical purposes comprising chemical agents, skin, cartilage and other cells; culture media for cultivating human cells for use in augmentation of bone and other tissues for medical purpose using induced pluripotent cells and embryonic stem-like cells and other stem cells; kit containing chemical media additives being cell growth media for growing cells for medical and veterinary purposes; culture media for cultivating human cells for use in regenerative medicine, oncology, hepatology and hematology; chemical, biochemical, biological, and cell biological products for medical purposes, namely, induced pluripotent stem cells (iPSCs), cell media, cell culture supplements and reagents for cell suspension, cell growth and cell storage; medicines, pharmaceutical products and preparations for health care, namely, induced pluripotent stem cells (iPSCs) and iPSC cultures; cell cultures and cell culture systems for human cells and for medical purposes, namely, induced pluripotent stem cells (iPSCs) and freeze-conserved cells, and reagents for sub cultivation of the cells; intestinal epithelial cell preparations for the treatment of gastrointestinal diseases; pharmaceutical preparations to evaluate the toxicity, metabolism, drug absorption and compound efficacy of the small intestines; medicinal preparations to evaluate the toxicity, metabolism, drug absorption and compound efficacy of the small intestines; intestinal epithelial cells for medical purposes; pharmaceutical preparations, namely, live cells in the nature of smooth muscle cells, skeletal muscle cells, myocytes, fibroblasts, chondrocytes, adipocytes, fibromyoblasts, ectodermal cells, hepatocytes, organ cells, liver cells, kidney cells, cardiac cells, pancreatic islet cells, cells present in the intestine, stem cells, osteoblasts, cells forming bone or cartilage, hematopoietic cells, parenchymal cells, stroma cells, totipotent cells (iTC), pluripotent cells (iPSC), and progenitor cells (iMSC) for medical purposes; biological implants, namely, live tissue intended for subsequent implantation; pharmaceutical preparations and drug delivery systems comprising chemical agents and stem cells for the treatment of osteoarthritis, cartilage defects, and cartilage injury; cells, epithelial cells, organoids and cell cultures for personalised medicine, namely, for diagnosis and treatment of diseases or disorders of epithelial tissue in the sensory, reproductive, urinary, digestive, circulatory, endocrine, nervous, lymphatic, integumentary, or respiratory systems; modified stem cells suitable for use as pharmaceutical biologicals used to regenerate neural and spinal cord tissues in humans
Pseudo MarkYIPS CELL
Goods and Servicesstem cell research services; research and development services in the field of cytology; custom cell culturing services for scientific and research purposes; testing, inspection, research and development of cell and tissue culturing; research and development of medicines; scientific investigations for medical purposes; custom design and development of chemical reagents scientific services relating to the isolation and cultivation of human tissues and cells for research purposes; research and development and consultation related thereto in the field of antibodies, antibody technology, chemistry, agrochemical pharmaceuticals, bioinformatics, biomedical devices, biologics, biotechnology, biotherapeutics, biology, biochemical preparations, cell lines, chemoinformatic, genetics and genetic engineering, gene expression systems, in vitro research, inhalation pharmaceuticals, molecular sciences, micro-organisms, nutrition, ophthalmic preparations, pharmacogenetics, pharmacokinetics, pharmacology, pharmaceuticals, polymers, peptide synthesis, protein, solid state characterization; scientific and technological services, namely, scientific research, development, analysis, testing, and technological services, namely, scientific research, development, analysis, testing, engineering, extraction, synthesis, purification and production in the field of antibodies, active pharmaceutical ingredients (API), biomolecules, cell bank characterization, chirality, chromosome aberration, clinical chemistry, cloning vector, cyclotides, DNA, flow cytometry, gas chromatography mass spectrometry, gene, immuno-pharmaceuticals, in vitro irritation, large molecule, liquid chromatography mass spectrometry, microbial, monomer, nanoparticle, natural products, peptides, proteins, RNA, supercritical fluid chromatography, small molecules and vaccines; biotechnology research; medical research and development in the field of tissue and cell fabrication; biologic services in the nature of biologic research; biomedical services, namely, laboratory services for human tissue, blood, blood components and stem cells for medical use; medical and scientific laboratory services, namely, development of induced pluripotent stem cells using cells derived from healthy and ill humans; medical and scientific laboratory services, namely, development of induced pluripotent stem cell lines using customized primary cells; medical and scientific laboratory services, namely, evaluating of drugs capable of differentiating various serovars suitable for diseases using induced pluripotent stem cells; medical and scientific laboratory services, namely, evaluating of drug efficacy for technology for making animal models of various diseases; medical and scientific laboratory services, namely, evaluating of the quality of induced pluripotent stem cells; medical services, namely, research services relating to stem cells; research, development and testing services for others in the fields of genomics, biotechnology, chemistry and pharmaceuticals; conducting clinical trials for others in the field of stem cell based therapies and products; scientific research services, namely, tracking, analyzing, forecasting, and reporting data in the field of clinical trials of stem cell based therapies and products

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, November 24, 2020
Primary Code005
First Use Anywhere DateFriday, December 31, 2021
First Use In Commerce DateFriday, December 31, 2021

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, November 24, 2020
Primary Code042
First Use Anywhere DateFriday, December 31, 2021
First Use In Commerce DateFriday, December 31, 2021

Trademark Owner History


Party NameCiSTEM Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressSeoul 06579
KR

Party NameCiSTEM Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSeoul 06579
KR

Party NameCiSTEM Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSeoul 06579
KR

Trademark Events


Event DateEvent Description
Tuesday, May 31, 2022NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, May 31, 2022REGISTERED-PRINCIPAL REGISTER
Saturday, April 23, 2022NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Friday, April 22, 2022ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Friday, April 22, 2022STATEMENT OF USE PROCESSING COMPLETE
Monday, April 11, 2022USE AMENDMENT FILED
Friday, April 22, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, April 11, 2022TEAS STATEMENT OF USE RECEIVED
Tuesday, February 8, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 14, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 14, 2021PUBLISHED FOR OPPOSITION
Wednesday, November 24, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 9, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, November 8, 2021EXAMINER'S AMENDMENT ENTERED
Monday, November 8, 2021NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Monday, November 8, 2021EXAMINERS AMENDMENT E-MAILED
Monday, November 8, 2021EXAMINERS AMENDMENT -WRITTEN
Friday, November 5, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, November 4, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, November 4, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, October 23, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Saturday, October 23, 2021NON-FINAL ACTION E-MAILED
Saturday, October 23, 2021NON-FINAL ACTION WRITTEN
Tuesday, October 19, 2021PREVIOUS ALLOWANCE COUNT WITHDRAWN
Tuesday, October 12, 2021WITHDRAWN FROM PUB - OG REVIEW QUERY
Monday, September 27, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, September 24, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, September 24, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, September 24, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, August 4, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, August 4, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, August 4, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, July 28, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, July 28, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, July 28, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, April 1, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, April 1, 2021NON-FINAL ACTION E-MAILED
Thursday, April 1, 2021NON-FINAL ACTION WRITTEN
Tuesday, March 9, 2021ASSIGNED TO EXAMINER
Tuesday, November 24, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Tuesday, October 13, 2020NEW APPLICATION ENTERED IN TRAM